Author

Hayuningbudi Saraswati

Johannes Gutenberg University Mainz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Ana CorrioneroiD· 2 shared Andreas KrämeriD· 2 shared Benedict‐Tilman BergeriD· 2 shared Daniela S. KrauseiD· 2 shared Lewis ElsoniD· 2 shared Martin P. SchwalmiD· 2 shared Patricia Alfonso· 2 shared Sandra RöhmiD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Ana CorrioneroORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors

Sebastian Mandel, Thomas Hanke, Niall Prendiville, María Baena-Nuevo, Lena M. Berger, Frederic Farges, Martin P. Schwalm, Benedict‐Tilman Berger, Andreas Krämer, Lewis Elson, Hayuningbudi Saraswati, Kamal Rayees Abdul Azeez, Verena Dederer, Sebastian Mathea, Ana Corrionero, , Stefan Knapp

This study develops a covalent LIMK1 inhibitor that selectively targets a unique cysteine, enabling isoform-specific studies of LIMK1 function.

Journal of Medicinal Chemistry · Jul 2, 2025Peer-reviewedBiochemistry

Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor

Sebastian Mandel, Thomas Hanke, Sebastian Mathea, Deep Chatterjee, Hayuningbudi Saraswati, Benedict‐Tilman Berger, Martin P. Schwalm, Satoshi Yamamoto, Michiko Tawada, Terufumi Takagi, Mahmood Ahmed, Sandra Röhm, Ana Corrionero, Patricia Alfonso, Maria Baena, , Stefan Knapp

The paper repurposes a benzoxazepinone scaffold originally designed for RIPK1 inhibition to develop a novel type-III LIMK1/2 inhibitor with high selectivity.

ACS Chemical Biology · Apr 14, 2025Peer-reviewedBiochemistry